Spyre Therapeutics Cash Flow Statement
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
85.69+5.79 (+7.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics free cash flow
In fiscal 2025, Spyre Therapeutics generated -$169.3 million of operating cash flow. That left free cash flow of -$169.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -155.20M | -208.02M | -338.79M | -83.81M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 0 | 0 | 744.00K | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K |
| Stock-Based Compensation | 37.61M | 44.83M | 25.68M | 7.11M | 8.04M | 6.26M | 4.88M | 4.28M | 2.49M | 1.22M |
| Change in Working Capital | -4.58M | -3.16M | 4.41M | -4.22M | 2.61M | -1.65M | 2.24M | 3.04M | -1.86M | -379.00K |
| Operating Cash Flow | -169.25M | -157.41M | -99.91M | -80.14M | -53.72M | -75.78M | -65.69M | -32.19M | -24.61M | -18.84M |
| Capital Expenditures | — | 0 | 0 | -38.00K | -573.00K | -4.28M | -1.49M | -422.00K | -619.00K | -212.00K |
| Investing Cash Flow | -143.47M | -353.29M | -108.39M | 57.01M | -22.62M | -7.60M | -1.74M | -15.23M | -22.53M | -12.08M |
| Financing Cash Flow | 309.02M | 410.91M | 361.08M | 42.68M | 1.39M | 154.51M | 65.72M | 57.07M | 12.21M | 49.37M |
| Net Change in Cash | -3.70M | -99.79M | 152.80M | 19.44M | -74.96M | 71.18M | -1.71M | 9.64M | -34.93M | 18.45M |
| Free Cash Flow | -169.25M | -157.41M | -99.91M | -80.18M | -54.29M | -80.06M | -67.18M | -32.62M | -25.23M | -19.05M |
This table shows 10 annual periods of Spyre Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a cash flow statement?